PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New artificial intelligence model accurately identifies which atrial fibrillation patients need blood thinners to prevent stroke

2025-09-01
(Press-News.org) Conference: “Late Breaking Science” presentation at the European Society of Cardiology - AI driven cardiovascular biomarkers and clinical decisions

Title: Graph Neural Network Automation of Anticoagulation Decision-Making

Date: Embargo lifts Monday, September 1, 4:00 pm EDT

Bottom Line: Mount Sinai researchers developed an AI model to make individualized treatment recommendations for atrial fibrillation (AF) patients—helping clinicians accurately decide whether or not to treat them with anticoagulants (blood thinner medications) to prevent stroke, which is currently the standard treatment course in this patient population. This model presents a completely new approach for how clinical decisions are made for AF patients and could represent a potential paradigm shift in this area.

In this study, the AI model recommended against anticoagulant treatment for up to half of the AF patients who otherwise would have received it based on standard-of-care tools. This could have profound ramifications for global health.

Why the study is important: AF is the most common abnormal heart rhythm, impacting roughly 59 million people globally. During AF, the top chambers of the heart quiver, which allows blood to become stagnant and form clots. These clots can then dislodge and go to the brain, causing a stroke. Blood thinners are the standard treatment for this patient population to prevent clotting and stroke; however, in some cases this medication can lead to major bleeding events.

This AI model uses the patient’s whole electronic health record to recommend an individualized treatment recommendation. It weighs the risk of having a stroke against the risk of major bleeding (whether this would occur organically or as a result of treatment with the blood thinner). This approach to clinical decision-making is truly individualized compared to current practice, where clinicians use risk scores/tools that provide estimates of risk on average over the studied patient population, not for individual patients. Thus, this model provides a patient-level estimate of risk, which it then uses to make an individualized recommendation taking into account the benefits and risks of treatment for that person.

The study could revolutionize the approach clinicians take to treat a very common disease to minimize stroke and bleeding events. It also reflects a potential paradigm change for how clinical decisions are made.

Why this study is unique: This is the first-known individualized AI model designed to make clinical decisions for AF patients using underlying risk estimates for the specific patient based on all of their actual clinical features. It computes an inclusive net-benefit recommendation to mitigate stroke and bleeding. 

How the research was conducted: Researchers trained the AI model on electronic health records of 1.8 million patients over 21 million doctor visits, 82 million notes, and 1.2 billion data points. They generated a net-benefit recommendation on whether or not to treat the patient with blood thinners.

To validate the model, researchers tested the model’s performance among 38,642 patients with atrial fibrillation within the Mount Sinai Health System. They also externally validated the model on 12,817 patients from publicly available datasets from Stanford.

Results: The model generated treatment recommendations that aligned with mitigating stroke and bleeding. It reclassified around half of the AF patients to not receive anticoagulation. These patients would have received anticoagulants under current treatment guidelines.

What this study means for patients and clinicians: This study represents a new era in caring for patients. When it comes to treating AF patients, this study will allow for more personalized, tailored treatment plans.

Quotes:  

“This study represents a profound modernization of how we manage anticoagulation for patients with atrial fibrillation and may change the paradigm of how clinical decisions are made,” says corresponding author Joshua Lampert, MD, Director of Machine Learning at Mount Sinai Fuster Heart Hospital. “This approach overcomes the need for clinicians to extrapolate population-level statistics to individuals while assessing the net benefit to the individual patient—which is at the core of what we hope to accomplish as clinicians. The model can not only compute initial recommendations, but also dynamically update recommendations based on the patient’s entire electronic health record prior to an appointment. Notably, these recommendations can be decomposed into probabilities for stroke and major bleeding, which relieves the clinician of the cognitive burden of weighing between stroke and bleeding risks not tailored to an individual patient, avoids human labor needed for additional data gathering, and provides discrete relatable risk profiles to help counsel patients.”

“This work illustrates how advanced AI models can synthesize billions of data points across the electronic health record to generate personalized treatment recommendations. By moving beyond the ‘one size fits none’ population-based risk scores, we can now provide clinicians with individual patient-specific probabilities of stroke and bleeding, enabling shared decision making and precision anticoagulation strategies that represent a true paradigm shift,”adds co-corresponding author Girish Nadkarni, MD, MPH, Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai.  

“Avoiding stroke is the single most important goal in the management of patients with atrial fibrillation, a heart rhythm disorder that is estimated to affect 1 in 3 adults sometime in their life”, says co-senior author, Vivek Reddy MD, Director ofCardiac Electrophysiology at the Mount Sinai Fuster Heart Hospital. “If future randomized clinical trials demonstrate that this Ai Model is even only a fraction as effective in discriminating the high vs low risk patients as observed in our study, the Model would have a profound effect on patient care and outcomes.”

“When patients get test results or a treatment recommendation, they might ask, ‘What does this mean for me specifically?’ We created a new way to answer that question. Our system looks at your complete medical history and calculates your risk for serious problems like stroke and major bleeding prior to your medical appointment. Instead of just telling you what might happen, we show you both what and how likely it is to happen to you personally. This gives both you and your doctor a clearer picture of your individual situation, not just general statistics that may miss important individual factors,” says co-first author Justin Kauffman, Data Scientiest with the Windreich Department of Artificial Intelligence and Human Health.

Mount Sinai Is a World Leader in Cardiology and Heart Surgery

Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital ranks No. 2 nationally for cardiology, heart, and vascular surgery, according to U.S. News & World Report®. It also ranks No. 1 in New York and No. 6 globally according to Newsweek’s “The World’s Best Specialized Hospitals.”  

It is part of Mount Sinai Health System, which is New York City's largest academic medical system, encompassing seven hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 9,000 primary and specialty care physicians; 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 48 multidisciplinary research, educational, and clinical institutes. Hospitals within the Health System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report's® “Best Hospitals” Honor Roll for 2025-2026.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.

For more Mount Sinai artificial intelligence news, visit: https://icahn.mssm.edu/about/artificial-intelligence.   

 

END


ELSE PRESS RELEASES FROM THIS DATE:

Safety of factor XI inhibition with abelacimab in atrial fibrillation by kidney function

2025-09-01
About The Study: In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function. These findings suggest that abelacimab may offer a particularly favorable safety profile among those with chronic kidney disease; however, larger studies are necessary to characterize the efficacy of abelacimab for stroke prevention in atrial fibrillation. Corresponding Author: To contact the corresponding author, Siddharth M. Patel, MD, MPH, email spatel@bwh.harvard.edu.  To access the embargoed study: Visit our For ...

Combination of mini-camera and AI predicts recurrent heart attack

2025-09-01
Measurements with a miniature camera inside the coronary arteries can accurately predict whether someone will suffer a recurrent heart attack. Until now, interpreting these images was so complex that only specialized laboratories could perform it. A new study from Radboud university medical center shows that AI can reliably take over this analysis and rapidly assess arteries for weak spots. A heart attack occurs when a coronary artery, which supplies the heart with blood, is blocked by a blood clot. This can occur when atherosclerosis causes artery narrowing, resulting in the heart receiving too little oxygen. Treatment typically ...

Study Reveals Details of Overactive Immune System in Patients with Chronic Fatigue Syndrome (ME/CFS)

2025-09-01
Patients with chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) have heightened innate immune responses to bacteria, viruses and fungi. While these responses are essential to fight infection, they can cause damage when unchecked. Led by researchers at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health with a multicenter team of leading ME/CFS researchers, the new study reveals molecular-level details into the syndrome’s lasting effects on inflammation and immune response that could inform the development of targeted therapeutic interventions to ...

UTSA and UT Health San Antonio complete merger to become The University of Texas at San Antonio

2025-09-01
SAN ANTONIO, Sept. 1, 2025 – UTSA and The University of Texas Health Science Center at San Antonio (UT Health San Antonio) today merged to form The University of Texas at San Antonio (UT San Antonio), a premier global university that is deeply committed to making lives better for the communities it serves. As a merged institution, UT San Antonio now ranks as the third-largest public research university in Texas according to annual research expenditures, behind only Texas A&M University and the University of Texas at Austin. UT San Antonio’s comprehensive enterprise now includes approximately 40,000 students, 17,000 employees and more than $486 million in annual ...

Helicobacter pylori screening after acute myocardial infarction

2025-09-01
About The Study: Among unselected patients with acute myocardial infarction, routine H pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding. Corresponding Author: To contact the corresponding author, Robin Hofmann, MD, PhD, email robin.hofmann@ki.se. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. Embed this link to provide your readers ...

Solar Orbiter traces superfast electrons back to Sun

2025-09-01
The European Space Agency-led Solar Orbiter mission has split the flood of energetic particles flung out into space from the Sun into two groups, tracing each back to a different kind of outburst from our star. The Sun is the most energetic particle accelerator in the Solar System. It whips up electrons to nearly the speed of light and flings them out into space, flooding the Solar System with so-called ‘Solar Energetic Electrons’ (SEEs). Researchers have now used Solar Orbiter to pinpoint the source of these energetic electrons and trace what we see out in space back to what’s actually ...

GaN-based electron beam technology from Nagoya University startup poised to overcome critical semiconductor manufacturing challenges at KIOXIA

2025-09-01
NAGOYA, Japan — In late September 2025, KIOXIA Iwate Corporation (Koichiro Shibayama CEO) will begin evaluating a GaN-based e-beam technology developed through joint research between Photo electron Soul Inc. (PeS; Takayuki Suzuki CEO), a Nagoya University startup, and the Amano–Honda Laboratory at Nagoya University. PeS has developed a next-generation electron gun specialized for GaN (gallium nitride) photocathodes and has demonstrated its effectiveness for semiconductor inspection and metrology (I&M), enabling electron microscopy of nanoscale transistors and high-aspect-ratio structures. These ...

Circle versus rectangle: Finding ‘Earth 2.0’ may be easier using a new telescope shape

2025-09-01
by Prof Heidi Newberg The Earth supports the only known life in the universe, all of it depending heavily on the presence of liquid water to facilitate chemical reactions. While single-celled life has existed almost as long as the Earth itself, it took roughly three billion years for multicellular life to form. Human life has existed for less than one 10 thousandth of the age of the Earth. All of this suggests that life might be common on planets that support liquid water, but it might be uncommon to find life that studies the universe and seeks to travel ...

Metformin changes blood metal levels in humans

2025-09-01
The widely used diabetes drug metformin changes blood metal levels in humans. The Kobe University study is an important step in understanding the drug’s many actions and designing better ones in the future. Metformin is the most widely prescribed diabetes drug in the world. Apart from lowering blood sugar levels, it is also known to have a broad range of beneficial side effects such as against tumors, inflammations and atherosclerosis. However, although it has been used for more than 60 years ...

Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation

2025-08-31
About The Study: Among patients without documented atrial arrhythmia recurrence after catheter ablation for atrial fibrillation, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy.  Corresponding Author: To contact the corresponding author, Boyoung Joung, MD, email cby6908@yuhs.ac. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ Editor’s Note: Please see the article for additional information, including other authors, author contributions and ...

LAST 30 PRESS RELEASES:

Crosswalk confusion: MA drivers flummoxed by pedestrian hybrid beacons, find UMass Amherst researchers

Study shows heart disease mortality disproportionately burdens low-income communities in California

Intracardiac echocardiography recognized as ‘transformative’ imaging modality in new SCAI position statement

Study finds ‘man’s best friend’ slows cellular aging in female veterans

To get representative health data, researchers hand out fitbits

Hiring in high-growth firms: new study explores the timing of organizational changes

Boosting work engagement through a simple smartphone diary

Climate change may create ‘ecological trap’ for species who can’t adapt

Scientists create ChatGPT-like AI model for neuroscience to build one of the most detailed mouse brain maps to date

AI and omics unlock personalized drugs and RNA therapies for heart disease

2023 ocean heatwave ‘unprecedented but not unexpected’

Johns Hopkins researchers develop AI to predict risk of US car crashes

New drug combination offers hope for men with advanced prostate cancer

New discovery finds gene converts insulin-producing cells into blood-sugar boosters

Powerful and precise multi-color lasers now fit on a single chip

Scientists agree chemicals can affect behavior, but industry workers more reluctant about safety testing

DNA nanospring measures cellular motor power

Elsevier Foundation and RIKEN launch “Envisioning Futures” report: paving the way for gender equity and women’s leadership in Japanese research

Researchers discover enlarged areas of the spinal cord in fish, previously found only in four-limbed vertebrates

Bipolar disorder heterogeneity decoded: transforming global psychiatric treatment approaches

Catching Alport syndrome through universal age-3 urine screening

Instructions help you remember something better than emotions or a good night’s sleep

Solar energy is now the world’s cheapest source of power, a Surrey study finds

Scientists reverse Alzheimer’s in mice using nanoparticles

‘Good’ gut bacteria boosts placenta for healthier pregnancy

USC team demonstrates first optical device based on “optical thermodynamics”

Microplastics found to change gut microbiome in first human-sample study

Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds

Plastic in the soil, but not as we know it: Biodegradable microplastics rewire carbon storage in farm fields

Yeast proteins reveal the secrets of drought resistance

[Press-News.org] New artificial intelligence model accurately identifies which atrial fibrillation patients need blood thinners to prevent stroke